Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Diagnostic and therapeutic challenges.

Hatef E, Ibrahim M, Nguyen QD, Do DV, Davis MJ, Rezaei KA, Kovach JL.

Retina. 2011 Jun;31(6):1218-23. doi: 10.1097/IAE.0b013e31820a675a. No abstract available.

PMID:
21386757
2.

Ranibizumab for the treatment of exudative age-related macular degeneration associated with retinal pigment epithelial tear.

Rouvas AA, Ladas ID, Georgalas I, Vergados I, Papakonstantinou D, Kotsolis AI.

Retina. 2011 Jun;31(6):1083-8. doi: 10.1097/IAE.0b013e318207d1a3.

PMID:
21427630
3.

Retinal pigment epithelium tear through the fovea with maintained visual acuity of 20/20.

Ilginis T, Thomassen VH.

Graefes Arch Clin Exp Ophthalmol. 2013 Apr;251(4):1243-4. doi: 10.1007/s00417-012-2102-9. Epub 2012 Jul 24. No abstract available.

PMID:
22825802
4.

Retinal pigment epithelium tears after intravitreal injection of ranibizumab for predominantly classic neovascular membranes secondary to age-related macular degeneration.

Konstantinidis L, Ambresin A, Zografos L, Mantel I.

Acta Ophthalmol. 2010 Nov;88(7):736-41. doi: 10.1111/j.1755-3768.2009.01547.x.

5.

Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study.

Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, Weichselberger A, Staurenghi G; SUSTAIN Study Group.

Ophthalmology. 2011 Apr;118(4):663-71. doi: 10.1016/j.ophtha.2010.12.019.

PMID:
21459217
6.

Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials.

Rosenfeld PJ, Shapiro H, Tuomi L, Webster M, Elledge J, Blodi B; MARINA and ANCHOR Study Groups.

Ophthalmology. 2011 Mar;118(3):523-30. doi: 10.1016/j.ophtha.2010.07.011.

PMID:
20920825
7.

Intravitreal infliximab in patients with macular degeneration who are nonresponders to antivascular endothelial growth factor therapy.

Arias L, Caminal JM, Badia MB, Rubio MJ, Catala J, Pujol O.

Retina. 2010 Nov-Dec;30(10):1601-8. doi: 10.1097/IAE.0b013e3181e9f942.

PMID:
21060271
8.

Retinal pigment epithelium tears following intravitreal ranibizumab therapy.

Kiss C, Michels S, Prager F, Geitzenauer W, Schmidt-Erfurth U.

Acta Ophthalmol Scand. 2007 Dec;85(8):902-3. Epub 2007 Apr 4.

9.

Subjective and functional deterioration in recurrences of neovascular AMD are often preceded by morphologic changes in optic coherence tomography.

Hoerster R, Muether PS, Hermann MM, Koch K, Kirchhof B, Fauser S.

Br J Ophthalmol. 2011 Oct;95(10):1424-6. doi: 10.1136/bjo.2010.201129. Epub 2011 Jul 18.

PMID:
21768186
10.

Adult-onset vitelliform detachment unresponsive to monthly intravitreal ranibizumab.

Kandula S, Zweifel S, Freund KB.

Ophthalmic Surg Lasers Imaging. 2010 Nov-Dec;41 Suppl:S81-4. doi: 10.3928/15428877-20101031-09.

PMID:
21117608
11.

The predictive value of subjective symptoms and clinical signs for the presence of treatment-requiring exudative age-related macular degeneration.

Hessellund A, Larsen DA, Bek T.

Acta Ophthalmol. 2012 Aug;90(5):471-5. doi: 10.1111/j.1755-3768.2010.02074.x. Epub 2011 Jan 14.

12.

Reading the signs: Microrips as a prognostic sign for impending RPE tear development.

Clemens CR, Alten F, Eter N.

Acta Ophthalmol. 2015 Nov;93(7):e600-2. doi: 10.1111/aos.12683. Epub 2015 Mar 8. No abstract available.

13.

Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion.

Spaide RF, Chang LK, Klancnik JM, Yannuzzi LA, Sorenson J, Slakter JS, Freund KB, Klein R.

Am J Ophthalmol. 2009 Feb;147(2):298-306. doi: 10.1016/j.ajo.2008.08.016. Epub 2008 Oct 17.

PMID:
18929354
14.

Significant improvements in near vision, reading speed, central visual field and related quality of life after ranibizumab treatment of wet age-related macular degeneration.

Frennesson C, Nilsson UL, Peebo BB, Nilsson SE.

Acta Ophthalmol. 2010 Jun;88(4):420-5. doi: 10.1111/j.1755-3768.2009.01576.x. Epub 2009 Aug 12.

15.

Functional and morphologic benefits in early detection of neovascular age-related macular degeneration using the preferential hyperacuity perimeter.

Lai Y, Grattan J, Shi Y, Young G, Muldrew A, Chakravarthy U.

Retina. 2011 Sep;31(8):1620-6. doi: 10.1097/IAE.0b013e31820d3ed1.

PMID:
21610564
16.

Enhanced S-Cone Syndrome and Macular Hole.

Arevalo JF, Kozak I.

JAMA Ophthalmol. 2015 Jun;133(6):e15108. doi: 10.1001/jamaophthalmol.2015.108. Epub 2015 Jun 11. No abstract available.

PMID:
26067693
17.

Diagnostic and therapeutic challenges.

Mukkamala SK, Yannuzzi LA, Agarwal A.

Retina. 2012 Nov-Dec;32(10):2171-4. doi: 10.1097/IAE.0b013e318263cf11. No abstract available.

PMID:
23026848
18.

Resolution of subretinal fluid associated with a spontaneous retinal pigment epithelial tear after intravitreal ranibizumab injection.

Gale J, Cheung J.

Can J Ophthalmol. 2009 Jun;44(3):345-6. doi: 10.3129/i09-064. No abstract available.

PMID:
19492002
19.

Inverted internal limiting membrane flap technique for large macular holes.

Michalewska Z, Michalewski J, Adelman RA, Nawrocki J.

Ophthalmology. 2010 Oct;117(10):2018-25. doi: 10.1016/j.ophtha.2010.02.011. Epub 2010 Jun 11.

PMID:
20541263
20.

Diagnostic and therapeutic challenges.

Ascaso FJ, Rojo M, Minguez E, Cohen SM, Yang SS.

Retina. 2011 Mar;31(3):616-22. doi: 10.1097/IAE.0b013e3181eac783. No abstract available.

PMID:
21336073

Supplemental Content

Support Center